Bioxytran (BIXT) Inventory (2010 - 2018)

Bioxytran (BIXT) posted Inventory of $6594.0 for Q2 2018, down 1.89% sequentially from $6721.0 in Q1 2018, and up 16.65% YoY from $5653.0 in Q2 2017.

Bioxytran (BIXT) Inventory (2010 - 2018) Analysis & Trends

Bioxytran has reported Inventory for 8 years, with the latest figure at $6594.0 in Q2 2018.

Quarterly Inventory rose 16.65% year-over-year to $6594.0 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $6594.0 (up 16.65% YoY) and the FY2017 annual result came in at $5264.0, down 16.07% from the prior year.
Inventory slipped to $6594.0 in Q2 2018 per BIXT's latest filing, from $6721.0 in the prior quarter.
Over five years, Inventory peaked at $14114.0 in Q1 2014 and troughed at $3642.0 in Q3 2016.
A 4-year average of $7712.0 and a median of $6272.0 in 2016 frame the typical range for Inventory.
The sharpest annual moves came in 2014 and 2017: Inventory dropped 23.97% in 2014, then jumped 51.35% in 2017.
Over 4 years, Inventory stood at $11114.0 in 2014, then tumbled by 43.57% to $6272.0 in 2016, then declined by 16.07% to $5264.0 in 2017, then climbed by 25.27% to $6594.0 in 2018.
According to Business Quant data, Inventory over the past three periods registered $6594.0, $6721.0, and $5264.0 for Q2 2018, Q1 2018, and Q4 2017 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Inventory (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	1.77 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	3.08 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	371.00 Mn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	280.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	732.60 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	97.11 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	142.38 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	128.86 Mn
10	Bioxytran	2.47 Mn	2.22 Mn	-	-

Download Data